Profile's ShareDataOnline
Google
 ASPEN
  • Home Page
    		•
  • Glossies
    		•
  • Forecasts
    		•
  • Email Alerts
    		•
    News
  • Latest News
    		•
  • Archive
    		•
  • SENS
    		•
  • Dir Dealings
    		•
    Fact Sheets
  • Summary
    		•
  • Detailed
    		•
  • Valuation
    		•
    Performance
  • Performance
    		•
  • Market Stats
    		•
  • Intraday
    		•
    Results
  • Comment
    		•
  • In Brief
    		•
  • Analysis
    		•
  • In Full
    		•
     
     Latest News: Aspen Pharmacare Holdings Ltd. ASPEN [APN]
     Mon, 20 Jul 2026 Official Announcement [DM] 
    Aspen - Aspen-Semaglutide approval
    Aspen has received Health Canada approval for its subsidiary, Aspen Pharmacare Canada Inc., to market Aspen-Semaglutide, a generic injectable for adults with type 2 diabetes to improve glycaemic control when combined with diet and exercise. Commercialisation is contingent on the supply of semaglutide active pharmaceutical ingredient from Dr Reddy's Laboratories Ltd., which has recently reported temporary supply constraints. The timing of market launch will depend on resolving these supply issues.
    Click here for original article
     
     
    Click here for full news archive for this company
    Closing price data source: JSE Ltd. All other statistics calculated by ProfileData.
       
    Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
    Other Profile Group sites: FundsData Online (unit trust data) | Profile Group corporate site
    [  Terms of Conditions |  Privacy Policy |  PAIA manual |  Site Map |  © Copyright Reserved 2026  ]
      


    Powered by ProfileData


    Follow us on:

    Show me the New ShareData Online message.